TLPPF (Telix Pharmaceuticals) Operating Cash Flow per Share : $0.08 (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Operating Cash Flow per Share?

Telix Pharmaceuticals's operating cash flow per share for the six months ended in Dec. 2024 was $0.01. Telix Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.08.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Telix Pharmaceuticals was 68.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Telix Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:

During the past 10 years, Telix Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 109.90% per year. The lowest was -27.20% per year. And the median was -26.80% per year.

TLPPF's 3-Year OCF Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 9.2
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

Telix Pharmaceuticals Operating Cash Flow per Share Historical Data

The historical data trend for Telix Pharmaceuticals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Operating Cash Flow per Share Chart

Telix Pharmaceuticals Annual Data

Trend

Sep99

Sep00

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

0.01

-0.15

-0.14

0.05

0.08

Telix Pharmaceuticals Semi-Annual Data
	Sep00	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Operating Cash Flow per Share	Get a 7-Day Free Trial												-0.01	0.03	0.02	0.08	0.01

Competitive Comparison of Telix Pharmaceuticals's Operating Cash Flow per Share

For the Biotechnology subindustry, Telix Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telix Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Telix Pharmaceuticals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Telix Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	27.251	/	345.188
	=	0.08

Telix Pharmaceuticals's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Dec. 2024 )	=	Cash Flow from Operations (Q: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2024 )
	=	2.5	/	351.473
	=	0.01

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.08

Telix Pharmaceuticals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

TLX:USA T3X:Germany TLX:Australia

Address

55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051

Website

https://www.telixpharma.com

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.